Larimar Therapeutics Inc: Tidbits from CEO Call Post Recent Updates for Nomlabofusin in FA

Research evidence excerpt

Larimar Therapeutics Inc: Tidbits from CEO Call Post Recent Updates for Nomlabofusin in FA

J P M O R G A N North America Equity Research

17 July 2026

Larimar Therapeutics Inc Overweight

LRMR, LRMR US

Tidbits from CEO Call Post Recent Updates for Price (16 Jul 26):$3.67

Nomlabofusp in FA

SMid Biotechnology

LRMR shares have been strong (up as much as 40%+ vs 5% NBI) since recent Tessa T Romero AC

updates, which we think is appropriate given the supportive additional open-label (1-212) 622-4484

(OL) data and a regulatory update that we view as encouraging (our note here). Along tessa.t.romero@jpmchase.com

these lines, we recently hosted Larimar Therapeutics’s CEO, Carole Ben-Maimon, to Caroline Pocher

address key investor questions following the company’s recent updates on (1-212) 622-8204

nomlabofusp (nomla) in Friedreich’s ataxia (FA). On the call, the CEO emphasized caroline.pocher@jpmchase.com

that the overarching “take-home” was that FA patients are expected to worsen over Mariam Waggeh

time, so the evidence of stabilization/improvement with nomla is meaningful; the (1-212) 622-1711

mariam.waggeh@jpmchase.com

CEO added that the market may be overemphasizing the anaphylaxis risk, without J.P. Morgan Securities LLC

fully accounting for its association with prior exposure and long stop/restart gaps (vs

intended continuous use), which is not how the drug is intended to be used and will

not be used in the real world. Further, mgmt reiterated confidence in continued rolling

BLA execution with the remaining modules to be submitted in 2H26 alongside dosing

of the first patient in the global confirmatory phase 3 trial planned for 3Q26 (U.S. sites

are up and running). We note that Larimar has had strong regulatory engagement for